Bradley McGregor, MD

Bradley A. McGregor, MD, discusses the challenges shared by oncologists who treat renal cell carcinoma.

Bradley A. McGregor, MD, discusses the advancements in treating metastatic renal cell carcinoma.

Bradley McGregor, MD, discusses how ongoing trials hold the key for further breakthroughs in genitourinary cancer treatment.

Bradley McGregor, MD, discusses background of the DAD trial evaluating sacituzumab govitecan-hziy in combination with enfortumab vedotin-ejfv for the treatment of patients with treatment-resistant metastatic urothelial carcinoma.

Bradley McGregor, MD, discusses the rationale behind the multi-institutional, prospective, single-arm phase 2 trial of cabozantinib, nivolumab, and ipilimumab for the treatment of patients with renal cell carcinoma with variant histologies.

In an interview with Targeted Oncology, Bradley A. McGregor, MD, discussed the main takeaways from a phase 3 study of cabozantinib, nivolumab, and ipilimumab for patients with renal cell carcinoma with variant histologies.

Expert genitourinary oncologists close their discussion with advice to community oncologists treating renal cell carcinoma.

A panel of experts on renal cell carcinoma discuss triplet therapy and review COSMIC-313, a study of cabozantinib, nivolumab, and ipilimumab in the first line.

Expert oncologists discuss the management of immune-related adverse events in renal cell carcinoma.

An overview of adverse event and toxicity considerations with TKI therapies in renal cell carcinoma.

Expert oncologists review data updates on IO-IO regimens in the treatment of advanced RCC, including CheckMate 214, and discuss treatment selection among IO-IO and IO-TKI combinations.

Multidisciplinary experts discuss the role of concurrent radiation in the treatment of renal cell carcinoma.

A panel of experts in renal cell carcinoma present the case of a 59-year-old woman with renal cell carcinoma and discuss systemic therapy options.

RCC experts discuss second-line therapy options following progression on first-line IO-TKI regimen.

Detailed insights on how the choice of tyrosine kinase inhibitors (TKIs) in IO-TKI regimens impact the treatment of advanced renal cell carcinoma.

In the third article of this series, Bradley McGregor, MD, gives comprehensive insights on treating patients with advanced renal cell carcinoma, with a focus on treatment sequencing.

Experts on renal cell carcinoma discuss frontline treatment options for favorable-risk disease and factors that impact treatment decisions.

A comprehensive discussion on how to select the appropriate IO-TKI regimen in the frontline setting in advanced renal cell carcinoma.

Bradley McGregor, MD, discusses the current landscape for advanced renal cell carcinoma therapies, emerging clinical evidence, and considerations for optimal treatment sequencing.

A panel of experts on renal cell carcinoma review updated data on IO-TKI regimens in advanced RCC, including the CheckMate 9ER, KEYNOTE-526, and CLEAR trials.

Expert oncologists give an overview of molecular testing, risk stratification, and treatment guidelines for renal cell carcinoma.

A panel of expert genitourinary oncologists give an overview of renal cell carcinoma and present the case of a 61-year-old man with metastatic clear cell RCC.

Bradley A. McGregor, MD, discusses current and future second-line therapy options following frontline tyrosine kinase inhibitor and immunotherapy for patients with advanced renal cell carcinoma.

Bradley A. McGregor, MD, discusses new trials of intensified combination regimens for frontline treatment of patients with intermediate- or poor-risk advanced renal cell carcinoma.

Bradley McGregor, MD, discusses the ongoing COSMIC-313 trial of cabozantinib, ipilimumab, and nivolumab in patients with renal cell carcinoma.

Bradley McGregor, MD, discusses the CheckMate-9ER trial of nivolumab plus cabozantinib versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.

Bradley McGregor, MD, discusses a small study that evaluated the combination of atezolizumab and bevacizumab for the treatment of patients with non-clear cell renal cell carcinoma.

Bradley McGregor, MD, discusses a trial investigating atezolizumab and bevacizumab in patients with metastatic renal cell carcinoma and variant histologies and/or sarcomatoid features.

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, senior physician, instructor in medicine, Harvard Medical School, discusses the goals of the phase III CheckMate-9ER trial, which is evaluating cabozantinib combined with nivolumab in previously untreated patients with advanced or metastatic renal cell carcinoma (RCC).